Bifidobacterium strain‐specific enhances the efficacy of cancer therapeutics in tumor‐bearing mice

Abstract

Colorectal cancer (CRC) is among the leading causes of cancer‐related death in the world. The development of CRC is associated with smoking, diet, and microbial exposure. Previous studies have shown that dysbiosis of the gut microbiome affects cancer development, because it leads to inflammation and genotoxicity. Supplementation with specific microbiota induces anti‐tumor effects by enhancing of anti‐tumor immunity. Here, we observed that supplementation with either of two B. breve strains reduces tumor growth in MC38 colon carcinoma‐bearing mice. Interestingly, only one B. breve strain boosted the efficacy of cancer therapeutics, including oxaliplatin and PD‐1 blockade. Extensive immune profiling and transcriptomic analysis revealed that the boosting B. breve strain augments lymphocyte‐mediated anti‐cancer immunity. Our results suggest that supple-mentation with B. breve strains could potentially be used as a strategy to enhance the efficacy of CRC therapeutics.